Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Statistical analysis was conducted using SPSS version 14.0
AOD9604 and Energy Balance Research In obese ob/ob and lean C57BL/6J mice treated for 14 days via mini-osmotic pumps, AOD9604 significantly reduced body weight gain in obese mice, associated with increased in vivo fat oxidation and increased plasma glycerol levels as an index of enhanced lipolysis without the hyperglycaemia or reduced insulin secretion associated with intact hGH treatment
Primary injection sites for AOD-9604 include the abdominal area (around the navel, varying position each injection), the front of the thighs (alternating legs), and the back of the upper arms (alternating arms)
however, this is a diagnostic laboratory test interference and not a drug interaction
US$ 23.28
US$ 24.21
US$ 22.98
US$ 23.83
US$ 24.56
US$ 28.36
